Brief: Rain Therapeutics Reports Qtrly Loss Per Share $0.70
10/11/2021 13:23
Nov 10 (Reuters) - Rain Therapeutics Inc RAIN.O :
* RAIN THERAPEUTICS REPORTS THIRD QUARTER 2021 FINANCIAL
RESULTS
AND HIGHLIGHTS RECENT PROGRESS
* RAIN THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.70
* RAIN THERAPEUTICS INC - EXPECTS ITS QUARTER-END CASH
POSITION TO
PROVIDE RUNWAY TO CONTINUE ADVANCING ITS RESEARCH AND
DEVELOPMENT PIPELINE AND COMPLETE ALL THREE PLANNED CLINICAL
TRIALS OF MILADEMETAN
Source text for Eikon: ID:nGNX38d1hf
Further company coverage: RAIN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rain Oncology
See all newsBrief: Rain Enhancement Technologies Holdco - May Offer Up To $25 Million In Securities From Time To Time - SEC Filing
Brief: Rain Enhancement Technologies Holdco Inc - Q1 And Q2 2025 Financial Statements Should Not Be Relied Upon Due To Accounting Error - SEC Filing
Brief: Rain Oncology Pursuant To Proposed Deal With Pathos AI
Brief: Rain Oncology To Be Acquired By Pathos AI For $1.16 In Cash Per Share Plus Contingent Value Rights
Brief: Rain Oncology Q3 Net Income USD -7.034 Million